Ellingson, Alexandra M.2010-05-212010-05-212010-04-21https://hdl.handle.net/11299/62360Additional contributors: Susan K. Rathe; David A. Largaespada (faculty mentor)Acute myeloid leukemia (AML) is the most common and most deadly type of leukemia in adults, affecting approximately 3 people per 100,000. AML is typically treated with a cocktail of chemotherapeutic drugs, most often involving the pharmaceutical agent cytosinearabinoside (Ara-C). Treatment with Ara-C will almost always cause remission in AML patients. However, developed resistance to Ara-C becomes a problem for many patients suffering from the disease, and many relapse within a few years of remission. We are using an in vitro system to model the Ara-C resistance in AML cell lines.en-USCollege of Biological SciencesBiology ProgramAcademic Health CenterDepartment of Genetics, Cell Biology and DevelopmentMasonic Cancer CenterPresentation